Cargando…

Regulation of Epidermal Growth Factor Receptor Signaling and Erlotinib Sensitivity in Head and Neck Cancer Cells by miR-7

Elevated expression and activity of the epidermal growth factor receptor (EGFR)/protein kinase B (Akt) signaling pathway is associated with development, progression and treatment resistance of head and neck cancer (HNC). Several studies have demonstrated that microRNA-7 (miR-7) regulates EGFR expres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalinowski, Felicity C., Giles, Keith M., Candy, Patrick A., Ali, Alishum, Ganda, Clarissa, Epis, Michael R., Webster, Rebecca J., Leedman, Peter J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480380/ https://www.ncbi.nlm.nih.gov/pubmed/23115635 http://dx.doi.org/10.1371/journal.pone.0047067

Ejemplares similares

miR-331-3p regulates expression of neuropilin-2 in glioblastoma
por: Epis, Michael R., et al.
Publicado: (2013)

Clinical Potential of microRNA-7 in Cancer
por: Horsham, Jessica L., et al.
Publicado: (2015)

microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB
por: Giles, Keith M., et al.
Publicado: (2016)

miR-331-3p and Aurora Kinase inhibitor II co-treatment suppresses prostate cancer tumorigenesis and progression
por: Epis, Michael R., et al.
Publicado: (2017)

EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy
por: Liu, Shuli, et al.
Publicado: (2020)

Inhibition of STAT3 by Niclosamide Synergizes with Erlotinib against Head and Neck Cancer
por: Li, Rui, et al.
Publicado: (2013)

Erlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma
por: Ngan, Hoi-Lam, et al.
Publicado: (2020)

Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib
por: Amri, Jamal, et al.
Publicado: (2019)

Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma
por: Stanam, Aditya, et al.
Publicado: (2016)

Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma
por: Setúbal Destro Rodrigues, Maria Fernanda, et al.
Publicado: (2018)

Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report
por: Thinn, Mie Mie, et al.
Publicado: (2019)

The tumor suppressor miR-642a-5p targets Wilms Tumor 1 gene and cell-cycle progression in prostate cancer
por: Beveridge, Dianne J., et al.
Publicado: (2021)

Oncogenic miR-9 is a target of erlotinib in NSCLCs
por: Chen, Xi, et al.
Publicado: (2015)

MAPK1(E322K) mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin
por: Wen, Yihui, et al.
Publicado: (2016)

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model
por: Bozec, A, et al.
Publicado: (2008)

Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts
por: IWAI, TOSHIKI, et al.
Publicado: (2011)

Novel Erlotinib–Chalcone Hybrids Diminish Resistance in Head and Neck Cancer by Inducing Multiple Cell Death Mechanisms
por: Murányi, József, et al.
Publicado: (2023)

Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/FBXW7 pathway
por: Zhang, Haiwei, et al.
Publicado: (2017)

Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas
por: William, William N., et al.
Publicado: (2018)

In-Depth Analysis Shows Synergy between Erlotinib and miR-34a
por: Zhao, Jane, et al.
Publicado: (2014)

2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells
por: Sobhakumari, Arya, et al.
Publicado: (2016)

MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma
por: Jain, Ankit P., et al.
Publicado: (2019)

Radiosensitization of head and neck cancer by targeting the epidermal growth factor receptor
por: Goel, Arun Kumar, et al.
Publicado: (2009)

Toxic epidermal necrolysis associated with nivolumab treatment for head and neck cancer
por: Koshizuka, Keiichi, et al.
Publicado: (2020)

The Role of HOXB9 and miR-196a in Head and Neck Squamous Cell Carcinoma
por: Darda, Lav, et al.
Publicado: (2015)

The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma
por: Doyle, Sean P, et al.
Publicado: (2018)

Epidermal Growth Factor Receptor Inhibition with Erlotinib Partially Prevents Cisplatin-Induced Nephrotoxicity in Rats
por: Wada, Yukihiro, et al.
Publicado: (2014)

Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET
por: Abourbeh, Galith, et al.
Publicado: (2015)

Alcohol-dysregulated miR-30a and miR-934 in head and neck squamous cell carcinoma
por: Saad, Maarouf A., et al.
Publicado: (2015)

miR-708-5p enhances erlotinib/paclitaxel efficacy and overcomes chemoresistance in lung cancer cells
por: Monteleone, Nicholas J., et al.
Publicado: (2020)

Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment
por: Orzáez, M, et al.
Publicado: (2012)

A Novel Insertion Mutation on Exon 20 of Epidermal Growth Factor Receptor, Conferring Resistance to Erlotinib
por: Khan, Nawazish A., et al.
Publicado: (2014)

MiR-3168, miR-6125, and miR-4718 as potential predictors of cisplatin-induced nephrotoxicity in patients with head and neck cancer
por: Quintanilha, Julia C. F., et al.
Publicado: (2021)

Prognostic Worth of Epidermal Growth Factor Receptor (EGFR) in Patients with Head and Neck Tumors
por: Barnes, Precious, et al.
Publicado: (2020)

miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor
por: ZHAO, FENG-YI, et al.
Publicado: (2016)

Clinicopathological characteristics and clinical morbidity in high‐risk head and neck cutaneous squamous cell carcinoma patients in Western Australia
por: Grover, Piyush, et al.
Publicado: (2022)

Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo
por: Cufí, Sílvia, et al.
Publicado: (2013)

Identification of miR-203a, mir-10a, and miR-194 as predictors for risk of lymphovascular invasion in head and neck cancers
por: Karmakar, Moumita, et al.
Publicado: (2021)

Dysregulated miR-645 affects the proliferation and invasion of head and neck cancer cell
por: Sun, Qiang, et al.
Publicado: (2015)

MiR-125 family improves the radiosensitivity of head and neck squamous cell carcinoma
por: Wang, Qi-Wei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a6hvshbii8ssmneubqiairn6i0